MiroDerm

MiroDerm is a biologic wound matrix medical device developed by Reprise Biomedical, Inc. It is a non-crosslinked acellular wound matrix derived from perfusion-decellularized porcine liver tissue. The product serves as a biologic scaffold that supports tissue repair and wound healing by retaining natural vascular pathways that facilitate cellular infiltration and integration. MiroDerm is indicated for the management of various wound types, including partial and full-thickness wounds, pressure ulcers, chronic vascular ulcers, venous ulcers, diabetic ulcers (including diabetic foot ulcers), tunneled and undermined wounds, trauma wounds, drainage wounds, and surgical wounds. It is applied topically, stored in a phosphate-buffered aqueous solution, and sterilized via electron beam irradiation. The product received FDA 510(k) clearance and has been commercially available since its transfer to Reprise Biomedical during a 2019 spin-off from Miromatrix Medical Inc.

Brand names

MiroDerm

Other names

MiroDerm Hepatic-Derived Wound Matrix